secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001104659-25-019531
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel: FDA inspection closed with VAI; SERENITY trial enrolling; Nasdaq compliance regained; CMO resigns
--------------------------------------------------------------------------------

- FDA closed TRANQUILITY II site inspection with 'Voluntary Action Indicated'; no regulatory action taken.
- SERENITY At-Home Phase 3 trial: 23 sites open, enrolling; topline data expected H2 2025 for sNDA.
- Regained compliance with Nasdaq minimum bid price rule; notice received Feb 28, 2025.
- Vincent J. O'Neill, M.D. resigned as EVP, Chief of Product Development and Medical Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925019531/0001104659-25-019531-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925019531/tm258055d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-019531

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer